CUSIP: 00900T107
Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
36,834,954
-
Share change
-
+1,784,704
-
Total reported value
-
$757,321,487
-
Price per share
-
$20.56
-
Number of holders
-
92
-
Value change
-
+$33,867,907
-
Number of buys
-
57
-
Number of sells
-
26
Quarterly Holders Quick Answers
What is CUSIP 00900T107?
CUSIP 00900T107 identifies AIMT - AIMMUNE THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2017
-
Previous quarter:
Q1 2017
Recent filing periods for CUSIP 00900T107:
Institutional Holders of AIMMUNE THERAPEUTICS INC - COM (AIMT) as of Q2 2017
As of 30 Jun 2017,
AIMMUNE THERAPEUTICS INC - COM (AIMT) was held by
92 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
36,834,954 shares.
The largest 10 holders included
Foresite Capital Management II, LLC, FMR LLC, Aisling Capital LLC, BlackRock Inc., VANGUARD GROUP INC, EAGLE ASSET MANAGEMENT INC, TLP GROUP LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., PRICE T ROWE ASSOCIATES INC /MD/, and Palo Alto Investors, LLC.
This page lists
92
institutional shareholders reporting positions in this security
for the Q2 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.